Virtu Financial’s Janux Therapeutics JANX Stock Holding History

Virtu Financial’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,667	Closed	-$162K	–	1923
2026 Q1	$162K	Buy	+11,667	New	+$160K	0.01%	1076
2025 Q1	–	Sell	-8,769	Closed	-$469K	–	1689
2024 Q4	$469K	Buy	8,769 +1,306	+17%	+$69.1K	0.02%	525
2024 Q3	$339K	Buy	7,463 +2,419	+48%	+$105K	0.02%	582
2024 Q2	$211K	Sell	5,044 -11,139	-69%	-$523K	0.01%	689
2024 Q1	$609K	Buy	+16,183	New	+$352K	0.05%	355

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Virtu Financial's JANX Position: Q2 2026 in Review

Virtu Financial sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 11,667 shares — an estimated $162K sold.

Virtu Financial first reported a position in JANX in Q1 2024 and held it in 5 quarters. The position peaked at $609K in Q1 2024. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Virtu Financial reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 11,667 Janux Therapeutics shares in Q2 2026, an estimated $162K.
Virtu Financial first reported a position in Janux Therapeutics in Q1 2024 and held it in 5 quarters.
Virtu Financial's Janux Therapeutics position peaked at $609K in Q1 2024.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.